Overview

Trametinib is a potent, reversible inhibitor of MEK1 and MEK2, the dual-specificity kinases immediately downstream of RAF in the RAS–RAF–MEK–ERK (MAPK) signaling cascade. By occupying the MEK ATP-binding pocket it prevents ERK phosphorylation, the event that would otherwise transmit proliferative signals from mutated RAS or BRAF into the nucleus. The 2 mg film-coated tablet in a 30-tablet pack is formulated for once-daily oral use under oncologist supervision.

How It Works

After a BRAF V600 or RAS mutation, the MAPK cascade runs continuously and drives cell-cycle progression. Trametinib binds MEK1/2 in an allosteric fashion, freezing the kinase in an inactive conformation so ERK cannot be phosphorylated. Because ERK controls transcription factors such as MYC and FOS, its suppression reduces the survival and division signals mutated cells rely on. Unlike RAF blockers, MEK inhibition acts one step below RAF, which is why trametinib is layered with a BRAF agent to shut the pathway at two points.

Indications

Trametinib is indicated for unresectable or metastatic melanoma carrying a BRAF V600E or V600K mutation, and for BRAF V600–mutant non-small cell lung cancer, often in combination with a BRAF inhibitor. It also contributes to the approved regimen for anaplastic thyroid carcinoma with the same mutation. Patient selection depends on validated BRAF mutation testing from tumor tissue or plasma, and treatment continues until disease progression or unacceptable toxicity.

Dosage & Administration

The standard oral dose is 2 mg taken once daily, with or without food, continuing until progression or limiting toxicity. Tablets should be swallowed whole and not crushed. Dose interruptions or reductions are managed per the prescribing protocol when febrile rash, cardiomyopathy, or ocular toxicity appear. Because trametinib is almost always paired with a BRAF inhibitor, the two agents are started together and their schedules coordinated by the treating clinician.

Storage & Sourcing

Store the 30-tablet pack at 2–8 °C in the original blister, protected from moisture and light. Brief room-temperature excursions are tolerated but prolonged heat degrades potency. Keep away from children. Buyers should confirm the manufacturer, batch number, and expiry on the carton before dispensing, and maintain a documented cold-chain record from warehouse to clinic.

FAQ

Q: How does trametinib differ from a BRAF inhibitor at the molecular level?

A: A BRAF inhibitor acts on the RAF kinase near the top of the MAPK cascade, while trametinib acts one level lower on MEK1/2. Blocking MEK prevents ERK phosphorylation regardless of whether the upstream trigger was mutant BRAF or mutant RAS, giving a complementary point of control.

Q: Why is MEK blockade often paired with BRAF inhibition?

A: Single-agent BRAF blockade can trigger paradoxical ERK reactivation through upstream feedback. Adding trametinib at the MEK level closes that loophole, deepening and prolonging pathway suppression in BRAF V600 tumors.

Q: What happens to the ERK signal when MEK is inhibited?

A: ERK phosphorylation falls, so the transcription factors it normally activates are no longer switched on. The downstream effect is reduced expression of proliferation and survival genes in the tumor cell.

Q: Does trametinib cross into the central nervous system?

A: CNS penetration is limited, which is one reason brain-metastatic disease is usually managed with combination regimens and close imaging rather than trametinib alone.